CD13 antibody (Alanyl (Membrane) Aminopeptidase)

Details for Product anti-ANPEP Antibody No. ABIN118526, Supplier: Log in to see
Antigen
  • Apn
  • pepN
  • SC8E4A.13
  • APN
  • CD13
  • GP150
  • LAP1
  • P150
  • PEPN
  • AP-M
  • AP-N
  • Cd13
  • Apm
  • KZP
  • Lap1
  • rAPN
  • APDE
  • p150
  • aminopeptidase N
  • aminopeptidase n
  • alanyl (membrane) aminopeptidase
  • Apn2
  • Apn1
  • SCO2643
  • pepN
  • Shewana3_0897
  • Alvin_1024
  • Ndas_3413
  • Arch_0473
  • Arch_0872
  • Saut_1544
  • Fbal_1877
  • ML5_3424
  • Despr_1988
  • Mesop_5365
  • ANPEP
  • Anpep
Alternatives
anti-Primate CD13 antibody for Blocking Antibody
Reactivity
Human, Primate
411
119
25
24
19
16
12
8
8
2
1
1
Host
Mouse
369
93
68
9
4
Clonality (Clone)
Monoclonal ()
Conjugate
This CD13 antibody is un-conjugated
67
63
34
16
12
9
9
9
9
7
7
7
7
7
7
6
5
5
4
3
2
2
2
2
1
Application
Enzyme Immunoassay (EIA), Functional Studies (Func), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunoprecipitation (IP)
397
141
131
89
84
80
80
37
33
8
8
6
4
2
2
2
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen Human AML cells.
Clone WM15
Isotype IgG1
Specificity The antibody recognises the Human CD13 cell surface glycoprotein, a 150 kDa molecule expressed by granulocytes and monocytes, and by myeloid leukaemia cells.
Purification Affinity Chromatography on Protein G
Alternative Name CD13 (ANPEP Antibody Abstract)
Background CD13 is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. This metalloprotease preferentially catalyzes removal of neutral amino acids from small peptides, thus activating or inactivating bioactive peptides. CD13 has also role in extracellular matrix degradation, antigen processing and signal transduction, is important in inflammatory responses, regulates intercellular contact, cell motility and vascularization. CD13 is involved in protection of leukemic cells against apoptosis and its expression associated with poor prognosis of carcinomas. CD13 functions as an aminopeptidase enzyme and is also a receptor for coronavirus.Synonyms: ANPEP, APN, Alanyl aminopeptidase, Aminopeptidase M, Aminopeptidase N, Microsomal aminopeptidase, Myeloid plasma membrane glycoprotein CD13, PEPN, gp150
Gene ID 290
NCBI Accession NP_001141
UniProt P15144
Research Area Stem Cells, Hematopoietic Progenitors, CD Antigens, Surface Receptors of Immune Cells, Extracellular Matrix, Signaling
Pathways Peptide Hormone Metabolism, Regulation of Systemic Arterial Blood Pressure by Hormones
Application Notes Flow Cytometry. Immunoprecipitation. Immunohistochemistry (frozen sections). ELISA.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. Further Comments: Clone WM15 inhibits infection of cells by human coronavirus and inhibits aminopeptidase N activity of the CD13 Molecule immunoprecipitates.
Restrictions For Research Use only
Concentration 1.0 mg/mL
Buffer PBS, pH ~7.4 containing 15 mM Sodium Azide as preservative
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Product cited in: McCormack, Muji?, Osdal, Bruserud, Gjertsen: "Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia." in: Blood, Vol. 121, Issue 7, pp. e34-42, 2013 (PubMed).

Favaloro, Browning, Facey: "CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated." in: Experimental hematology, Vol. 21, Issue 13, pp. 1695-701, 1993 (PubMed).

Bradstock, Favaloro, Kabral, Kerr, Hughes, Musgrove: "Myeloid progenitor surface antigen identified by monoclonal antibody." in: British journal of haematology, Vol. 61, Issue 1, pp. 11-20, 1985 (PubMed).

Background publications Tavernier, Boiron, Huguet, Bradstock, Vey, Kovacsovics, Delannoy, Fegueux, Fenaux, Stamatoullas, Tournilhac, Buzyn, Reman, Charrin, Boucheix, Gabert, Lheritier, Vernant, Dombret, Thomas, , ,: "Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 21, Issue 9, pp. 1907-14, 2007 (PubMed).

Petrovic, Schacke, Gahagan, OConor, Winnicka, Conway, Mina-Osorio, Shapiro: "CD13/APN regulates endothelial invasion and filopodia formation." in: Blood, Vol. 110, Issue 1, pp. 142-50, 2007 (PubMed).

Terauchi, Kajiyama, Shibata, Ino, Nawa, Mizutani, Kikkawa: "Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells." in: BMC cancer, Vol. 7, pp. 140, 2007 (PubMed).

Tokuhara, Hattori, Ishida, Hirai, Higashiyama, Kodama, Miyake: "Clinical significance of aminopeptidase N in non-small cell lung cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 13, pp. 3971-8, 2006 (PubMed).